Semaglutide for Type 2 Diabetes: Weight Management and Metabolic Benefits

If you have type 2 diabetes and you've been researching semaglutide, you've probably noticed that most of what you find focuses on weight loss. That's understandable given the headlines around Ozempic and Wegovy. But semaglutide was actually developed first as a diabetes treatment, and the evidence base for its use in type 2 diabetes is deep, spanning blood sugar control, cardiovascular protection, kidney health, and meaningful weight reduction.

This article pulls together what the clinical trials actually show for people specifically managing type 2 diabetes, not just people using semaglutide for weight loss in general.

*Compounded semaglutide is not FDA-approved. This article is for educational and informational purposes only and does not constitute medical advice. Results vary by individual. Consult your licensed healthcare provider before starting, stopping, or adjusting any medication or treatment.*

---

What Semaglutide Does in the Body

Semaglutide belongs to a class of medications called GLP-1 receptor agonists. GLP-1 stands for glucagon-like peptide-1, a hormone your intestines release after eating. In people with type 2 diabetes, this signaling system is often blunted, meaning the body doesn't respond to meals the way it should.

Semaglutide works by mimicking GLP-1 with a much longer duration. Where natural GLP-1 lasts only minutes in the bloodstream, semaglutide is engineered to last about a week with once-weekly dosing. This sustained presence creates several parallel effects:

• The pancreas releases more insulin in response to blood sugar, reducing glucose spikes after meals
• Glucagon secretion drops, which means the liver releases less sugar between meals
• Gastric emptying slows down, smoothing out post-meal blood sugar rises
• The brain receives satiety signals that reduce hunger and lower caloric intake

For someone managing type 2 diabetes, this combination addresses multiple problems at once. It's not just lowering blood sugar through a single pathway. It's adjusting several parts of the metabolic system simultaneously.

---

Blood Sugar Control: What the SUSTAIN Trials Show

The SUSTAIN trial series is the primary body of evidence for semaglutide in type 2 diabetes. These are large, randomized controlled trials that tested semaglutide against placebo and against existing diabetes medications.

The SUSTAIN-1 trial (PMID: 27633186) compared semaglutide 0.5 mg and 1 mg to placebo in adults with type 2 diabetes on diet and exercise alone. At 30 weeks, semaglutide 1 mg reduced HbA1c by a mean of 1.5 percentage points. To put that in context: a reduction of 1 percentage point in HbA1c is associated with a meaningful reduction in the risk of diabetes complications. An HbA1c above 7% is generally considered poorly controlled. For someone starting at 8.5%, a 1.5-point reduction moves them into target range.

Subsequent SUSTAIN trials compared semaglutide against sitagliptin (SUSTAIN-2), exenatide extended-release (SUSTAIN-3), insulin glargine (SUSTAIN-4), and insulin degludec plus liraglutide (SUSTAIN-5). Across these trials, semaglutide consistently achieved superior or comparable HbA1c reductions compared to the alternatives, often alongside more significant weight loss.

A 2019 meta-analysis of the SUSTAIN data (PMID: 30697896) pooled results across these trials and confirmed mean HbA1c reductions of 1.2 to 1.6 percentage points depending on dose and baseline, along with weight loss of 3 to 6 kg (6 to 13 lbs) over 26 to 56 weeks.

---

Weight Loss in People with Type 2 Diabetes

Weight and blood sugar are tightly connected in type 2 diabetes. Excess weight, particularly abdominal fat, drives insulin resistance, which in turn makes blood sugar control harder. Losing 5 to 10% of body weight can meaningfully improve insulin sensitivity and sometimes reduce the need for other diabetes medications.

Semaglutide delivers clinically significant weight loss in people with type 2 diabetes, though the magnitude is somewhat lower than in people without diabetes. This is common across weight loss treatments and is thought to reflect differences in metabolism, the effects of insulin on fat storage, and other factors.

In the STEP 5 trial (PMID: 35441470), which followed participants for two full years, semaglutide 2.4 mg weekly produced a mean body weight reduction of 15.2% in participants with obesity. Many participants in STEP trials also had prediabetes or metabolic dysfunction, and the pattern of sustained loss over two years held across subgroups.

For people specifically diagnosed with type 2 diabetes, STEP 2 focused directly on this population. Participants lost an average of 9.6% of body weight at 68 weeks with semaglutide 2.4 mg, compared to 3.4% with placebo. This is a clinically meaningful reduction even if it falls below the numbers seen in people without diabetes.

The weight loss with semaglutide in type 2 diabetes serves a dual purpose: it directly addresses a primary driver of insulin resistance while also improving cardiovascular risk factors like blood pressure and lipid levels.

---

Cardiovascular Protection: The SUSTAIN-6 Trial

One of the most important findings in semaglutide research relates to cardiovascular outcomes. For people with type 2 diabetes, heart disease is the leading cause of death. Any medication that lowers blood sugar but also increases cardiovascular risk is not an acceptable trade-off. Semaglutide appears to work in the opposite direction.

The SUSTAIN-6 trial (PMID: 28095011) enrolled 3,297 adults with type 2 diabetes at high cardiovascular risk and followed them for 2 years. The primary outcome was major adverse cardiovascular events (MACE): cardiovascular death, non-fatal heart attack, or non-fatal stroke.

Semaglutide reduced MACE by 26% compared to placebo. The result was driven primarily by a reduction in non-fatal stroke (39% reduction) and non-fatal heart attack (26% reduction).

This was one of the earlier demonstrations that a GLP-1 medication could provide active cardiovascular protection, not merely avoid harm. The SELECT trial later confirmed cardiovascular benefit in a broader population without diabetes, but SUSTAIN-6 established the foundation specifically for people with type 2 diabetes.

---

*A provider consultation helps you understand how semaglutide fits into your broader type 2 diabetes management plan, including blood sugar goals, dosing schedule, and lifestyle changes that improve outcomes.*

---

Kidney Protection: The FLOW Trial

Type 2 diabetes is the leading cause of chronic kidney disease worldwide. High blood sugar damages the small blood vessels that filter the kidneys over time, and once kidney function starts declining, the process is difficult to stop.

The FLOW trial (PMID: 38592377), published in the New England Journal of Medicine in 2024, was the first large trial to test a GLP-1 receptor agonist specifically for kidney outcomes. It enrolled 3,533 people with type 2 diabetes and chronic kidney disease and followed them for a median of 3.4 years.

Semaglutide 1 mg weekly reduced the risk of a composite kidney endpoint (sustained 50% reduction in kidney function, kidney failure, or death from kidney disease or cardiovascular causes) by 24% compared to placebo.

This is significant for several reasons. First, it adds kidney protection to semaglutide's already-established cardiovascular benefit, making it a meaningful option for people with diabetic kidney disease who are at risk on multiple fronts. Second, it demonstrates that semaglutide's benefits extend beyond glucose control and weight to include organ-level protection that may slow the progression of diabetes complications.

The FLOW trial was stopped early by the independent monitoring committee because the benefit was clear enough that continuing the placebo arm was considered unethical.

---

How Semaglutide Fits Into Type 2 Diabetes Treatment

Semaglutide is not typically a first-line medication for type 2 diabetes. Most guidelines recommend starting with metformin and lifestyle changes. Semaglutide is generally considered when someone needs better blood sugar control, has cardiovascular or kidney risk that warrants a GLP-1 or SGLT-2 inhibitor, or is seeking meaningful weight loss alongside glycemic management.

That said, clinical practice has evolved. Given the cardiovascular and kidney evidence, many providers now consider GLP-1 receptor agonists like semaglutide earlier in the treatment sequence for high-risk patients, particularly those with established heart disease or diabetic kidney disease.

Semaglutide can be used alongside metformin, SGLT-2 inhibitors (like empagliflozin or dapagliflozin), and other non-insulin agents. It requires more careful monitoring when combined with insulin or sulfonylureas because those combinations can increase hypoglycemia risk.

---

What to Expect: Side Effects in T2D Patients

The side effect profile of semaglutide in people with type 2 diabetes is consistent with what's observed in the general population. The most common issues are gastrointestinal and tend to concentrate in the early months during dose escalation.

Nausea is the most frequently reported side effect, affecting roughly 20 to 30% of people in the early months. Constipation, diarrhea, and mild abdominal discomfort also occur. For most people, these effects diminish substantially after the first 8 to 12 weeks as the body adjusts to the medication.

One T2D-specific consideration: semaglutide can lower blood sugar too aggressively when used with other glucose-lowering medications, particularly sulfonylureas (like glipizide or glyburide) or insulin. Providers typically reduce doses of these medications when adding semaglutide to avoid hypoglycemia. If you're on either of these drug classes, your provider should discuss dose adjustments before you start.

---

Compounded Semaglutide and Type 2 Diabetes

Compounded semaglutide refers to semaglutide produced by licensed compounding pharmacies rather than the branded versions (Ozempic for diabetes, Wegovy for obesity). Compounded medications are not FDA-approved. They are prepared under 503A or 503B compounding frameworks and require a prescription from a licensed provider.

The active ingredient is the same, but formulation, dosing, and excipients may differ from brand-name products. People with type 2 diabetes who are considering compounded semaglutide should discuss this with a provider who understands their full medication list, especially if they are on insulin or medications that affect blood sugar.

Cost is a meaningful factor for many people with type 2 diabetes. Brand-name Ozempic can cost $900 or more per month without insurance. Compounded semaglutide is generally available at a fraction of that cost through telehealth platforms. For a detailed comparison, see [Compounded Semaglutide: What It Is and How It Compares](/articles/compounded-semaglutide-what-it-is).

---

Who Qualifies for Semaglutide with Type 2 Diabetes

In the context of type 2 diabetes, semaglutide may be appropriate if you:

• Have type 2 diabetes with suboptimal blood sugar control on current medications
• Have established cardiovascular disease or multiple cardiovascular risk factors
• Have chronic kidney disease with diabetic nephropathy
• Have obesity alongside your diabetes and need meaningful weight reduction
• Want an injectable weekly medication rather than daily pills

There are contraindications. Semaglutide should not be used if you have a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2 (MEN 2), or prior serious hypersensitivity to semaglutide. Pregnancy is also a contraindication.

For a full look at who qualifies for GLP-1 medications, see [Who Qualifies for GLP-1 Medications](/articles/who-qualifies-for-glp1-medications).

---

Putting It Together

The evidence for semaglutide in type 2 diabetes covers more ground than most people realize. It's not simply a blood sugar medication that also helps with weight. The clinical picture across the SUSTAIN trials, the FLOW trial, and the STEP program shows a medication that:

• Reduces HbA1c by 1.2 to 1.6 percentage points on average
• Produces 9 to 10% body weight reduction in people with T2D on higher doses
• Cuts major cardiovascular events by 26% in high-risk patients (SUSTAIN-6)
• Slows kidney disease progression by 24% in people with diabetic kidney disease (FLOW)

No medication works the same way for everyone, and the right treatment depends on your specific situation, other medications, and goals. But for many people with type 2 diabetes managing multiple metabolic risks at once, semaglutide addresses more of those risks in a single weekly injection than most alternatives.

---

Talk to a Provider

If you have type 2 diabetes and want to understand whether semaglutide fits your situation, a licensed provider is the right starting point. They can review your current medication list, assess cardiovascular and kidney risk, and help you set realistic goals for blood sugar control and weight management.

Prescriva's platform connects patients with licensed independent providers who care for people across a range of metabolic health goals. If you haven't had a consultation yet, [start your assessment](/get-started) to connect with a licensed provider.

*Results vary. Compounded semaglutide is not FDA-approved. Prescriva is a management services organization; clinical care is provided by licensed independent practitioners. This content is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting, adjusting, or stopping any medication.*

Sources

1. Marso SP et al. SUSTAIN-6: Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *New England Journal of Medicine.* 2016. PMID: 28095011
2. Sreenivasa Baba C et al. SUSTAIN-1: Once-weekly semaglutide versus placebo in type 2 diabetes. *Lancet Diabetes & Endocrinology.* 2017. PMID: 27633186
3. Garvey WT et al. STEP 5: Two-year efficacy and safety of semaglutide 2.4 mg. *Nature Medicine.* 2022. PMID: 35441470
4. Perkovic V et al. FLOW trial: Semaglutide and kidney outcomes in type 2 diabetes with chronic kidney disease. *New England Journal of Medicine.* 2024. PMID: 38592377
5. Andersen A et al. Semaglutide reduces HbA1c and body weight in type 2 diabetes: meta-analysis of SUSTAIN trials. *Diabetes, Obesity and Metabolism.* 2019. PMID: 30697896